Ohio State survey finds healthcare AI comfort declining
The national poll found that 42% of U.S. adults were open to AI use in their care, down from 52% in 2024.
A national survey commissioned by the Ohio State University Wexner Medical Center found that public comfort with AI in healthcare fell from 2024 to 2025. The poll included 1,007 U.S. adults and was conducted in January.
Only 42% of respondents said they were open to AI being used as part of their care, down from 52% in 2024. The share who believed AI could make some health processes more efficient also declined, from 64% to 55%.
More than half of adults surveyed said they had used AI to make important health decisions without consulting a medical professional, according to Ohio State. Among respondents who used AI for health-related purposes, 62% used it to understand symptoms before deciding whether to seek care.
Other reported uses included explaining test results or a medical diagnosis, cited by 44% of health-related AI users. A smaller share used AI to compare treatment options or make a treatment decision, at 25%, while 20% used it to prepare for an upcoming medical appointment.
The findings contrast with Ohio State’s 2024 survey, which found broader support for some AI use cases in care delivery, including reducing wait times, minimizing human errors, and taking notes during appointments.
“There’s a strong value for using artificial intelligence as augmented intelligence,” said Ravi Tripathi, MD, chief health informatics officer at Ohio State Wexner Medical Center. He said patients should have oversight of the technology but consult their healthcare team for a final plan.
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
SimonMed highlights role in large global X-ray AI study
The study analyzed 258,373 X-rays from 100 medical centers across 26 countries and evaluated the Rayvolve AI Suite across trauma, chest, measurement, and bone age use cases.
Former RadNet CTO joins Neurophet as scientific advisor
The neuroradiologist and former RadNet CTO will advise the neuroimaging AI company as it seeks to strengthen clinical validation and U.S. market expansion.
CMR-CLIP AI model interprets cardiac MRI scans with high accuracy
The model was trained on more than 13,000 cardiac MRI studies and linked moving heart images with clinical radiology reports, according to the research team.
Flywheel-AWS link creates governed imaging layer for trials
The integration combines AWS HealthImaging’s cloud-based DICOM storage with Flywheel’s imaging data orchestration tools for clinical trials, research, and AI development.
Free HelloAI training targets practical healthcare AI adoption
The company is making the HelloAI Professional track available at no cost, adding more than 20 hours of on-demand healthcare AI education.
Siemens links coronary CT planning to cath-lab PCI guidance
The system combines Syngo.CT Coronary Cockpit and Syngo PCI Connect to transfer preprocessed coronary CT angiography data into the cath lab.
AZmed gets FDA clearance for expanded AZtrauma scope
The clearance expands AZtrauma beyond fracture detection to include joint effusions and dislocations on X-rays in adults and children ages 2 years and older.
HOPPR breast imaging model converts 2D mammograms into text
The HOPPR EB 2D Mammo Narrative Model generates structured narrative output from 2D mammography images for breast imaging workflow applications.
DeepHealth secures AI clearances for neuro, prostate tools
The regulatory milestones cover Neuro Suite Brain Health and Brain Age, LumbarMR, and Prostate AI within DeepHealth’s clinical AI portfolio.
Philips SmartIQ aims to cut coronary imaging radiation dose
The coronary imaging technology adds an ultra-low-dose protocol for Philips’ Azurion image-guided therapy platform and is available in Europe and selected markets.
Azra AI, RevealDx partner on lung nodule AI
Azra AI will integrate RevealAI-Lung into its incidental findings and oncology workflow platform.
Accuro XV clearance gives Rivanna path into MSK ultrasound
Rivanna received FDA 510(k) clearance for Accuro XV, a diagnostic ultrasound system for musculoskeletal imaging. The company is also developing AI tools for bone visualization and fracture detection.